Company: RNAC
Filing Date: 2025-10-08
Form Type: 8-K
Source: 0001453687-25-000104
Chunk: 1

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-10-08
Form: 8-K
Item: Item 5.02
Chunk 1
---
 based on actual performance or, if the termination occurs during the first quarter of the calendar year, based on her target bonus, and (iii) direct payment of, or reimbursement for, continued medical, dental and/or vision coverage pursuant to COBRA for up to six months. The Company must provide Ms. Seymour 30 days’ notice, or pay in lieu of notice, in the event the Company terminates her for any reason other than for cause.

Ms. Seymour has also agreed to refrain from (i) engaging in competition with the Company while employed and following her termination of employment other than due to a layoff or by the Company without cause for a period of 12 months, (ii) soliciting customers, suppliers, vendors or other business partners of the Company while employed and for a period of 12 months following her termination of employment for any reason, and (iii) soliciting employees of the Company while employed and for a period of 12 months following her termination for any reason.

Pursuant to the Employment Agreement, Ms. Seymour is entitled to receive a sign-on bonus in the amount of $80,000 and was granted an option to purchase 50,000 shares of the Company’s common stock, par value $0.0001 per share, at an exercise price equal to the closing price per share of the Company’s common stock on the grant date (which will be the Effective Date). The option will vest over a four-year period, with 25% vesting 12 months from the grant date and the remaining 75% vesting in three equal annual installments thereafter, subject to Ms. Seymour’s continued employment with the Company on each vesting date.

Also in connection with her appointment as Chief Accounting Officer, Ms. Seymour has entered into the Company’s standard form of indemnification agreement for executives.

There are no arrangements or understandings between Ms. Seymour and any other person pursuant to which she was selected as an officer, and there are no family relationships between Ms. Seymour and any of the Company’s directors or executive officers. Ms. Seymour has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

Blaine Davis, the Company’s Chief Financial Officer, will continue to be designated as both the Company's principal financial officer and principal accounting officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf